Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones Mirum announces concurrent private placement of $210 million, funding upfront payment Expands Mirum’s leadership in rare liver disease with two commercial products and a near-term Phase 3 label expansion opportunity Advances Travere’s strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation Mirum t...
Source: marketscreener.com
